Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Unicycive Therapeutics Inc | UNCY | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.135 | 03:23:37 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.135 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.47 - 1.8227 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 1.135 | USD |
Unicycive Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 39.27M | 34.75M | - | 675k | -31.41M | -0.90 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Unicycive Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical UNCY Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.04 | 1.289 | 0.9333 | 1.15 | 702,425 | 0.095 | 9.13% |
| 1 Month | 1.56 | 1.60 | 0.9333 | 1.19 | 484,546 | -0.425 | -27.24% |
| 3 Months | 1.20 | 1.818 | 0.9333 | 1.35 | 426,044 | -0.065 | -5.42% |
| 6 Months | 0.5545 | 1.818 | 0.47 | 1.17 | 301,468 | 0.5805 | 104.69% |
| 1 Year | 1.35 | 1.8227 | 0.47 | 1.20 | 207,843 | -0.215 | -15.93% |
| 3 Years | 8.55 | 8.73 | 0.4004 | 1.95 | 737,848 | -7.42 | -86.73% |
| 5 Years | 8.55 | 8.73 | 0.4004 | 1.95 | 737,848 | -7.42 | -86.73% |
Unicycive Therapeutics Description
| Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. |
